Urinary detection of rapid-acting insulin analogs in healthy humans

被引：15

作者：

Judak, Peter ^{[1
]}

Coppieters, Gilles ^{[1
]}

Lapauw, Bruno ^{[2
]}

Van Eenoo, Peter ^{[1
]}

Deventer, Koen ^{[1
]}

机构：

[1] Univ Ghent, Dept Diagnost Sci, Doping Control Lab, Technol Pk 30, B-9052 Zwijnaarde, Belgium

[2] Ghent Univ Hosp, Dept Endocrinol, Ghent, Belgium

来源：

DRUG TESTING AND ANALYSIS | 2020年 / 12卷 / 11-12期

关键词：

elimination time; healthy volunteers; insulins; mass spectrometry; urine; LIQUID-CHROMATOGRAPHY; MASS-SPECTROMETRY;

D O I：

10.1002/dta.2817

中图分类号：

Q5 [生物化学];

学科分类号：

071010 ; 081704 ;

摘要：

Human insulin and its synthetic analogs are considered as life-saving drugs for people suffering from diabetes mellitus. Next to the therapeutic use, scientific and non-scientific literature (e.g. bodybuilding forums; antidoping intelligence and investigation reports) indicate that these prohibited substances are used as performance enhancing agents. In the present report, the development and validation of a sensitive analytical strategy is described for the urinary detection of three rapid-acting insulin analogs (Lispro, Aspart, Glulisine). The method is based on sample purification by the combination of ultrafiltration and immunoaffinity purification and subsequent analysis by nano-flow liquid chromatography coupled to high resolution mass spectrometry. Next to the results on different validation parameters (LOD: 10 pg/mL; recovery: 25-48%; matrix effect: -3-(-8) %), data on urinary elimination times, which were obtained in the frame of an administration study with the participation of healthy volunteers, are presented. The determined detection windows (9 hours) are expected to help to evaluate current routine analytical methods and aim to aid doping authorities to set appropriate target windows for efficient testing.

引用

页码：1629 / 1635

页数：7